Rapid Micro Biosystems (NasdaqCM:RPID) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnn-Kate Heller - Senior Vice President of Investor RelationsDan Arias - Managing DirectorMichael Beaulieu - VP of Investor Relations and Corporate CommunicationsRobert Spignesi - CEO and PresidentSean Wirtjes - CFOConference Call ParticipantsBrendan Smith - Tools/Dx AnalystThomas Flaten - Senior Research AnalystOperatorGood day, and thank you for standing by.Welcome to the Rapid Micro Biosystems Q4 a ...

Ollie's Bargain Outlet (NasdaqGM:OLLI) Q4 2026 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsChuck Grom - Managing DirectorEric van der Valk - President and CEOJohn Swygert - Executive ChairmanJoshua Young - Equity Research AssociateKate McShane - Managing DirectorRobert Helm - EVP and CFOSteven Zaccone - Director of Equity ResearchConference Call ParticipantsAnthony Chukumba - Managing Director and Senior Research AnalystEdward Kelly - Managing Director and Senior Equity Research AnalystJere ...

Vera Bradley (NasdaqGS:VRA) Q4 2026 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsIan Bickley - Chairman and CEOMark Dely - Chief Administrative OfficerMartin Layding - Former CFOConference Call ParticipantsEric Beder - CEO and Consumer AnalystOperatorGreetings, and welcome to the Vera Bradley fourth quarter fiscal 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require ...

Ollie's Bargain Outlet (NasdaqGM:OLLI) Q4 2026 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsChuck Grom - Managing DirectorEric van der Valk - President and CEOJohn Swygert - Executive ChairmanJoshua Young - Equity Research AssociateKate McShane - Managing DirectorRobert Helm - EVP and CFOSteven Zaccone - Director of Equity ResearchConference Call ParticipantsAnthony Chukumba - Managing Director and Senior Research AnalystEdward Kelly - Managing Director and Senior Equity Research AnalystJere ...

Scholar Rock FY Conference Summary Company Overview - **Company**: Scholar Rock (NasdaqGS:SRRK) - **Industry**: Biotechnology - **Foundation**: Established in 2012, celebrating its fiftieth anniversary in 2026 - **Focus**: Development of antibody technology to inhibit difficult growth factors, particularly myostatin [2][3] Core Points and Arguments - **Myostatin Inhibition Success**: Scholar Rock has achieved a significant milestone by successfully inhibiting myostatin, leading to the first positive pivotal trial for treating spinal muscular atrophy (SMA) after decades of attempts by the industry [3] - **Regulatory Approvals**: The company is awaiting FDA and EMA approval for its lead asset, apitegromab, with plans for commercial launches in the U.S. and Europe in 2026 [5][49] - **Debt Instrument**: Scholar Rock announced a $550 million debt instrument to fund operations, with an additional $100 million expected to be drawn down by the end of the quarter [5][9] - **Clinical Trials**: The company is advancing its pipeline with key Phase 2 clinical trials, including: - OPAL study for apitegromab combined with gene therapy for infants and toddlers with SMA [6] - FORGE study for facioscapulohumeral muscular dystrophy (FSHD) involving 60 patients [59][61] Financial Position - **Cash Balance**: Ended the year with a cash balance of $368 million before the additional $100 million drawdown [9] - **Priority Review Voucher (PRV)**: Scholar Rock qualifies for a rare pediatric disease priority review voucher, expected to be monetized upon approval, with a value ranging between $150 million and $200 million [11][33] Market Strategy - **Global Expansion**: Plans to build a 50-country operating platform, targeting approximately 35,000 patients with SMA, with a focus on Germany as the first European market post-EMA approval [49][50] - **Patient Assistance Programs**: Launching "Scholar Rock Supports" and "Life Takes Muscle" disease education programs to assist patients and families [16][17] Regulatory Challenges - **Compliance Issues**: The delay in approval for apitegromab is due to compliance issues at the fill-finish facility owned by Novo Nordisk, which has affected the timeline for resubmission [13][27] - **Resubmission Timeline**: The company anticipates a Class 2 resubmission for FDA review, which could take up to six months, but is hopeful for a quicker turnaround based on previous experiences [29][32] Innovation and Future Directions - **Subcutaneous Formulation**: Development of a subcutaneous version of apitegromab is underway, with plans to stage discussions with regulators post-approval of the IV formulation [52][57] - **Focus on FSHD**: The rationale for targeting FSHD with apitegromab is based on the success in SMA and the potential to address muscle dysfunction in this patient population [61][64] Additional Insights - **KOL Engagement**: Ongoing discussions with key opinion leaders (KOLs) in the SMA community have been positive, highlighting the need for muscle-targeted therapies [17][19] - **Market Access in Germany**: Germany is expected to be the first country for launch in Europe due to established access and reimbursement processes [45][49] This summary encapsulates the key points discussed during the Scholar Rock FY Conference, highlighting the company's strategic direction, financial health, regulatory challenges, and innovative approaches in the biotechnology sector.

TIC Solutions (NYSE:TIC) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAlex Rygiel - Managing Director and Head of Equity ResearchAndrew Shen - Director of Investor RelationsBen Heraud - President and COOHarold Antor - Senior Equity Research AssociateKristin Schultes - CFORobbie Franklin - Executive ChairmanTal Pizzey - CEOTomohiko Sano - Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorHello, and welcome to the TIC Solutions fourth quarter 2025 earning ...

Financial Data and Key Metrics Changes - Full year net sales were $1.41 billion, in line with guidance despite reduced marketing spend and lower traffic [8] - Adjusted EBITDA was $78 million, exceeding guidance of $70 million [8] - Pro forma adjusted EBITDA margin was approximately 9%, a 200 basis point improvement versus the prior year [39] - Gross profit margin for Q4 was 55.6%, a 430 basis point decline year-over-year, primarily due to a non-recurring inventory obsolescence charge [36] Business Line Data and Key Metrics Changes - The ComfortMode mattress launched in January saw sales 3.5 times expectations, nearly twice the sales of the three c-series beds it replaces [14] - The company is reducing its core lineup from 12 mattresses to 7, organized into three clear collections [17] - Operating expenses for the full year were $824 million, a $136 million reduction from the prior year [39] Market Data and Key Metrics Changes - Brand consideration among premium shoppers grew 10%, achieving the highest consideration in the premium category [24] - The company experienced significant increases in critical consideration drivers, including value, quality, and comfort [25] Company Strategy and Development Direction - The company is focused on executing a turnaround strategy that includes growth and cost-cutting measures [6] - A new product line is being launched to address customer needs for comfort, durability, and value [15] - The marketing strategy has been modernized to improve customer acquisition and brand strength [22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged pressures from severe weather and macroeconomic impacts affecting sales at the start of the year [11] - The company expects Q1 net sales to decline in the high teens percentage due to early-year softness, but anticipates significant improvement in Q2 [45] - Adjusted EBITDA for the full year is expected to increase in the high teens to mid-20s percentage range year-over-year [46] Other Important Information - The company has identified $50 million of additional annualized cost savings that are currently being executed [31][60] - Total liquidity at year-end was $58 million, well above the amended $30 million covenant floor [40] Q&A Session Summary Question: What were the main pain points addressed by the new product launches? - Management focused on expanding the audience to serve existing customers and attract younger demographics, emphasizing comfort, value, and durability [52] Question: What are the major sources of the $50 million of additional savings? - The savings will come from logistics, delivery, labor model resets, and corporate overhead structure adjustments [59] Question: What is the phasing for getting the new beds across the portfolio? - The new beds will be available for purchase starting March 23rd, with most stores set by mid-April [72] Question: Will the EBITDA growth reference the reported number or the pro forma number? - The growth will reference the reported adjusted EBITDA base of $78 million [75] Question: Will marketing spend trend back up in 2026? - Marketing spend will be held flat in 2026 compared to 2025, with increased spending in Q2, Q3, and Q4 [86]

CareCloud (NasdaqGM:CCLD) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsA. Hadi Chaudhry - Chief Strategy OfficerBrendan Covello - Corporate CounselMahmud Haq - Founder and Executive ChairmanMichael Galantino - PresidentNorman Roth - Interim CFO and Corporate ControllerStephen Snyder - CEOConference Call ParticipantsAllen Klee - Managing Director and Equity Research AnalystMichael Kim - Senior Research AnalystOperatorGreetings. Welcome to CareCloud, Inc.'s fourth quarter 2025 results ...

Village Farms International (NasdaqCM:VFF) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAaron Grey - Managing Director of Equity ResearchAnn Gillin Lefever - COOFrederico Gomes - Director of Institutional Research for Life SciencesMichael DeGiglio - President and CEOSteve Ruffini - Executive VP, Director, and CFOOperatorGood morning, ladies and gentlemen. Welcome to Village Farms International's fourth quarter and year-end 2025 financial results conference call. This morning, Village ...

Pharming Group (NasdaqGM:PHAR) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnurag Relan - CMOFabrice Chouraqui - CEOJoseph Pantginis - Managing Director, Equity ResearchKenneth Lynard - CFOLaVerne Marsh - Chief Commercial OfficerConference Call ParticipantsJeff Jones - Managing Director and Senior AnalystLucy Codrington - Research AnalystNatalia Webster - AnalystSheila Hernandez - AnalystSimon Scholes - Senior AnalystOperatorGood day, thank you for standing by. Welcome to the Pharmi ...